GWS
TEVA icon

Greykasell Wealth Strategies’s Teva Pharmaceuticals TEVA Stock Holding History

Greykasell Wealth Strategies’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-700
Closed -$10.8K – 346
2025
Q1 		$10.8K Buy
+700
New +$12.5K 0.01% 256

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Greykasell Wealth Strategies's TEVA Position: Q2 2025 in Review

Greykasell Wealth Strategies sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 700 shares — an estimated $10.8K sold.

Greykasell Wealth Strategies first reported a position in TEVA in Q1 2025 and held it in 1 quarter. The position peaked at $10.8K in Q1 2025. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Greykasell Wealth Strategies reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Greykasell Wealth Strategies sold 700 Teva Pharmaceuticals shares in Q2 2025, an estimated $10.8K.
  • Greykasell Wealth Strategies first reported a position in Teva Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Greykasell Wealth Strategies's Teva Pharmaceuticals position peaked at $10.8K in Q1 2025.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Greykasell Wealth Strategies's 13F filing for Q2 2025, filed 11 Aug 2025.